Abstract Search

ea0094p399 | Neuroendocrinology and Pituitary | SFEBES2023

Paltusotine maintains IGF-1, GH, and symptom control in patients with acromegaly switched from injected octreotide or lanreotide monotherapy: Topline results from PATHFNDR-1, a phase 3, randomized, double-blind, placebo-controlled, multicenter study

R. Gadelha Monica , Casagrande, MD, PhD Alessandra , J. Strasburger MD Christian , Bidlingmaier Martin , Snyder MD Peter , Guitelman MD Mirtha , Boguszewski MD Cesar , Buchfelder MD Michael , Shimon MD Ilan , Raverot MD Gerald , Toth MD Miklos , Mezosi MD Emese , Doknic MD Mirjana , Fan PhD Xiaolin , Clemmons MD David , Keeley PhD Michael , J. Trainer MD Peter , Struthers PhD R. Scott , Krasner MD Alan , M.K. Biller MD Beverly

Paltusotine is a once-daily, oral, selectively-targeted SST2 agonist in development for the treatment of acromegaly. PATHFNDR-1 (NCT04837040) enrolled patients with acromegaly who had an IGF-1 ≤1xULN on a stable (>12 weeks) dose of lanreotide or octreotide. Patients were randomized 1:1 to receive paltusotine 40 mg/day or placebo for 36 weeks. During the first 24 weeks, the paltusotine dose was titrated (range 20-60 mg) based on IGF-1 and tolerance. Dose changes were ...

1 shares

Endocrine Abstracts

Paltusotine maintains IGF-1, GH, and symptom control in patients with acromegaly switched from injected octreotide or lanreotide monotherapy: Topline results from PATHFNDR-1, a phase 3, randomized, double-blind, placebo-controlled, multicenter study

BiosciAbstracts